Pathogenic mutations in BRCA1 and BRCA2 genes are thus predictive biomarkers for PARPi sensitivity in breast, ovarian, pancreatic, and prostate cancers, and are approved as companion test for PARPi indications [3]. The gene discussed is BRCA1; the disease is prostate cancer.